EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Obicetrapib and ezetimibe enhance LDL receptor-mediated VLDL clearance and regress atherosclerosis on atorvastatin background

José A Inia, Leo H Zhang, Nanda Keijzer, Nicole Worms, Anita van Nieuwkoop-van Straalen, Marc Ditmarsch, Mathijs de Kleer, J Wouter Jukema, John J P Kastelein, Michael Szarek, Anita M van den Hoek, Geurt Stokman und 2 weitere

Journal of Lipid Research · 2026-05 · 67 (5) · 101028

DOI: 10.1016/j.jlr.2026.101028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Lipid Research, 2026-05. Verfasst von José A Inia und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Research, The Netherlands Organization for Applied Scientific Research (TNO), Leiden, the Netherlands; Department of Cardiol…. Hauptthemen laut MEDLINE: Atherosclerosis, Atorvastatin, Ezetimibe, Receptors, LDL. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NewAmsterdam Pharma, TNO.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisAtorvastatinEzetimibeReceptors, LDLLipoproteins, VLDLAnimalsMiceAnticholesteremic AgentsMaleCholesterol Ester Transfer Proteins

Stichwörter der Autor:innen

CETPHDL cholesterolatherosclerosisezetimibenon-HDL cholesterolobicetrapibregression

Substanzen

AtorvastatinEzetimibeReceptors, LDLAnticholesteremic AgentsCholesterol Ester Transfer ProteinsLipoproteins, VLDL

Autor:innen und Institutionen

  • Department of Biomedical Research, The Netherlands Organization for Applied Scientific Research (TNO), Leiden, the Netherlands; Department of Cardiology, Leiden University Medical Center (LUMC), Leiden, the Netherlands;…
  • Department of Biomedical Research, The Netherlands Organization for Applied Scientific Research (TNO), Leiden, the Netherlands.
  • NewAmsterdam Pharma, Naarden, the Netherlands.
  • Department of Cardiology, Leiden University Medical Center (LUMC), Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, the Netherlands; Netherlands Heart Institute, Utrecht, t…
  • NewAmsterdam Pharma, Naarden, the Netherlands; Department of Vascular Medicine, Amsterdam UMC, Amsterdam, the Netherlands.
  • CPC Clinical Research and Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA; State University of New York, Downstate School of Public Health, Brooklyn, NY, USA.

Förderung

  • NewAmsterdam Pharma
  • TNO

Zitieren

APA

Inia, J. A., Zhang, L. H., Keijzer, N., Worms, N., van Nieuwkoop-van Straalen, A., Ditmarsch, M., de Kleer, M., Jukema, J. W., Kastelein, J. J. P., Szarek, M., van den Hoek, A. M., Stokman, G., Pieterman, E. J., & Princen, H. M. G. (2026). Obicetrapib and ezetimibe enhance LDL receptor-mediated VLDL clearance and regress atherosclerosis on atorvastatin background. Journal of Lipid Research, 67(5), 101028. https://doi.org/10.1016/j.jlr.2026.101028

Vancouver

Inia JA, Zhang LH, Keijzer N, Worms N, van Nieuwkoop-van Straalen A, Ditmarsch M, et al. Obicetrapib and ezetimibe enhance LDL receptor-mediated VLDL clearance and regress atherosclerosis on atorvastatin background. Journal of Lipid Research. 2026;67(5):101028. doi:10.1016/j.jlr.2026.101028

BibTeX
@article{Inia2026,
  author = {Inia, José A and Zhang, Leo H and Keijzer, Nanda and Worms, Nicole and van Nieuwkoop-van Straalen, Anita and Ditmarsch, Marc and de Kleer, Mathijs and Jukema, J Wouter and Kastelein, John J P and Szarek, Michael and van den Hoek, Anita M and Stokman, Geurt and Pieterman, Elsbet J and Princen, Hans M G},
  title = {Obicetrapib and ezetimibe enhance LDL receptor-mediated VLDL clearance and regress atherosclerosis on atorvastatin background},
  journal = {Journal of Lipid Research},
  year = {2026},
  volume = {67},
  number = {5},
  pages = {101028},
  doi = {10.1016/j.jlr.2026.101028}
}
Kostenlos starten →